J Bousquet1,2, D P Caimmi3,4, A Bedbrook1, M Bewick5, P W Hellings6, P Devillier7, S Arnavielhe8, C Bachert9, K C Bergmann10,11, G W Canonica12, N H Chavannes13, A A Cruz14,15, R Dahl14,15, P Demoly3,4, G De Vries16, E Mathieu-Dupas8, A Finkwagner17, J Fonseca18,19, N Guldemond20, T Haahtela21, B Hellqvist-Dahl22, J Just23, T Keil24,25, L Klimek26, M L Kowalski27, M Kuitunen28, P Kuna29, V Kvedariene30, D Laune8, A M Pereira18,19, P Carreiro-Martins31,32, E Melén33,34, M Morais-Almeida35, J Mullol36, A Muraro37, R Murray38, L Nogueira-Silva39,40, N G Papadopoulos41,42, G Passalacqua12, F Portejoie1, D Price43, D Ryan44, B Samolinski45, A Sheikh46, V Siroux47, O Spranger17, A Todo Bom48, P V Tomazic49, A Valero50, E Valovirta51,52, A Valiulis53,54, O VandenPlas55, S van der Meulen56, M van Eerd16, M Wickman33,34, T Zuberbier10,11. 1. MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France. 2. INSERM, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, U1168 Paris, and UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Yvelines, France. 3. CHRU de Montpellier, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Sorbonne Universités, Paris, France. 4. Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France. 5. iQ4U Consultants Ltd, London, UK. 6. Department of Microbiology and Immunology, Laboratory of Clinical Immunology, KU Leuven, Leuven, Belgium. 7. Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pôle des Maladies Respiratoires, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Versailles, France. 8. Kyomed, Montpellier, France. 9. ENT Department, Upper Airways Research Laboratory, Ghent University Hospital, Ghent, Belgium. 10. Department of Dermatology and Allergy, Comprehensive Allergy-Centre-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany. 11. Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany. 12. Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy. 13. Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands. 14. ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brasil. 15. GARD Executive Committee, Geneva, Switzerland. 16. Peercode BV, Gerdermalsen, The Netherlands. 17. Global Allergy and Asthma Platform GAAPP, Vienna, Austria. 18. Center for Health Technology and Services Research - CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. 19. Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal. 20. Institute of Health Policy and Management iBMG - Erasmus Universit, Rotterdam, The Netherlands. 21. Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland. 22. Department of Respiratory Diseases, Odense University Hospital, Odense, Denmark. 23. Allergology Department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Sorbonne Universités, Paris, France. 24. Institute of Social Medicine, Epidemiology and Health Economics, Charité -Universitätsmedizin Berlin, Berlin, Germany. 25. Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany. 26. Center for Rhinology and Allergology, Wiesbaden, Germany. 27. Department of Immunology, Rheumatology and Allergy, Healthy Ageing Reseach Centre (HARC), Medical University of Lodz, Lodz, Poland. 28. Children's Hospital, University of Helsinki and University Hospital of Helsinki, Helsinki, Finland. 29. Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland. 30. Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania. 31. CEDOC, Respiratory Research Group, Nova Medical School, Campo dos Martires da Patria, Lisbon, Portugal. 32. Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal. 33. Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden. 34. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 35. Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisboa, Portugal. 36. ENT Department, Hospital Clinic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Catalonia, Spain. 37. Department of Women and Child Health, Food Allergy Referral Centre Veneto Region, Padua General University Hospital, Padua, Italy. 38. Medical Communications Consultant, MedScript Ltd, Dundalk, Co Louth, Ireland. 39. Center for Health Technology and Services Research - CINTESIS, Porto, Portugal. 40. Department of Internal Medicine, Centro Hospitalar Sao Joao, Porto, Portugal. 41. Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK. 42. Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital "P&A Kyriakou", University of Athens, Athens, Greece. 43. Observational and Pragmatic Research Institute, Singapore and Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK. 44. Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK. 45. Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland. 46. Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK. 47. INSERM, Université Grenoble Alpes, IAB, U 1209, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Université Joseph Fourier, Grenoble, France. 48. Imunoalergologia, Centro Hospitalar Universitario de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 49. Medical University of Graz, ENT University Hospital Graz, Graz, Austria. 50. Pneumology and Allergy Department, CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. 51. Department of Lung Diseases and Clinical Allergology, University of Turku, Turku, Finland. 52. Department of Allergy Clinic, Terveystalo, Turku, Finland. 53. Vilnius University Clinic of Children's Diseases and Public Health Institute, Vilnius, Lithuania. 54. European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium. 55. Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. 56. Attorney at law, Axon Lawyers, the Netherlands. Role: provision of legal services.
Abstract
BACKGROUND: The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms). AIMS: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions. METHODS: The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms. RESULTS: By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. CONCLUSIONS: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods.
BACKGROUND: The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms). AIMS: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions. METHODS: The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms. RESULTS: By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. CONCLUSIONS: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods.
Authors: Michael S Deiner; Stephen D McLeod; James Chodosh; Catherine E Oldenburg; Cherie A Fathy; Thomas M Lietman; Travis C Porco Journal: Invest Ophthalmol Vis Sci Date: 2018-02-01 Impact factor: 4.799
Authors: Grzegorz Kardas; Michał Panek; Piotr Kuna; Janusz Cieszyński; Przemysław Kardas Journal: Front Pharmacol Date: 2020-05-21 Impact factor: 5.810
Authors: J Bousquet; G L Onorato; C Bachert; M Barbolini; A Bedbrook; L Bjermer; J Correia de Sousa; N H Chavannes; A A Cruz; E De Manuel Keenoy; P Devillier; J Fonseca; S Hun; T Kostka; P W Hellings; M Illario; J C Ivancevich; D Larenas-Linnemann; J Millot-Keurinck; D Ryan; B Samolinski; A Sheikh; A Yorgancioglu; I Agache; S Arnavielhe; M Bewick; I Annesi-Maesano; J M Anto; K C Bergmann; C Bindslev-Jensen; S Bosnic-Anticevich; J Bouchard; D P Caimmi; P Camargos; G W Canonica; V Cardona; A M Carriazo; C Cingi; E Colgan; A Custovic; R Dahl; P Demoly; G De Vries; W J Fokkens; J F Fontaine; B Gemicioğlu; N Guldemond; Z Gutter; T Haahtela; B Hellqvist-Dahl; E Jares; G Joos; J Just; N Khaltaev; T Keil; L Klimek; M L Kowalski; I Kull; P Kuna; V Kvedariene; D Laune; R Louis; A Magnan; J Malva; E Mathieu-Dupas; E Melén; E Menditto; M Morais-Almeida; R Mösges; J Mullol; R Murray; H Neffen; R O'Hehir; S Palkonen; N G Papadopoulos; G Passalacqua; J L Pépin; F Portejoie; D Price; B Pugin; F Raciborski; F E R Simons; M Sova; O Spranger; C Stellato; A Todo Bom; P V Tomazic; M Triggiani; A Valero; E Valovirta; O VandenPlas; A Valiulis; M van Eerd; M T Ventura; M Wickman; I Young; T Zuberbier; A Zurkuhlen; A Senn Journal: Clin Transl Allergy Date: 2017-10-23 Impact factor: 5.871
Authors: J Bousquet; S Arnavielhe; A Bedbrook; M Bewick; D Laune; E Mathieu-Dupas; R Murray; G L Onorato; J L Pépin; R Picard; F Portejoie; E Costa; J Fonseca; O Lourenço; M Morais-Almeida; A Todo-Bom; A A Cruz; J da Silva; F S Serpa; M Illario; E Menditto; L Cecchi; R Monti; L Napoli; M T Ventura; G De Feo; D Larenas-Linnemann; M Fuentes Perez; Y R Huerta Villabolos; D Rivero-Yeverino; E Rodriguez-Zagal; F Amat; I Annesi-Maesano; I Bosse; P Demoly; P Devillier; J F Fontaine; J Just; T P Kuna; B Samolinski; A Valiulis; R Emuzyte; V Kvedariene; D Ryan; A Sheikh; P Schmidt-Grendelmeier; L Klimek; O Pfaar; K C Bergmann; R Mösges; T Zuberbier; R E Roller-Wirnsberger; P Tomazic; W J Fokkens; N H Chavannes; S Reitsma; J M Anto; V Cardona; T Dedeu; J Mullol; T Haahtela; J Salimäki; S Toppila-Salmi; E Valovirta; B Gemicioğlu; A Yorgancioglu; N Papadopoulos; E P Prokopakis; S Bosnic-Anticevich; R O'Hehir; J C Ivancevich; H Neffen; E Zernotti; I Kull; E Melen; M Wickman; C Bachert; P Hellings; S Palkonen; C Bindslev-Jensen; E Eller; S Waserman; M Sova; G De Vries; M van Eerd; I Agache; T Casale; M Dykewickz; R N Naclerio; Y Okamoto; D V Wallace Journal: Clin Transl Allergy Date: 2018-10-25 Impact factor: 5.871
Authors: Oliver Pfaar; Ludger Klimek; Marek Jutel; Cezmi A Akdis; Jean Bousquet; Heimo Breiteneder; Sharon Chinthrajah; Zuzana Diamant; Thomas Eiwegger; Wytske J Fokkens; Hans-Walter Fritsch; Kari C Nadeau; Robyn E O'Hehir; Liam O'Mahony; Winfried Rief; Vanitha Sampath; Manfred Schedlowski; María José Torres; Claudia Traidl-Hoffmann; De Yun Wang; Luo Zhang; Matteo Bonini; Randolf Brehler; Helen Annaruth Brough; Tomás Chivato; Stefano R Del Giacco; Stephanie Dramburg; Radoslaw Gawlik; Aslı Gelincik; Karin Hoffmann-Sommergruber; Valerie Hox; Edward F Knol; Antti Lauerma; Paolo M Matricardi; Charlotte G Mortz; Markus Ollert; Oscar Palomares; Carmen Riggioni; Jürgen Schwarze; Isabel Skypala; Eva Untersmayr; Jolanta Walusiak-Skorupa; Ignacio J Ansotegui; Claus Bachert; Anna Bedbrook; Sinthia Bosnic-Anticevich; Luisa Brussino; Giorgio Walter Canonica; Victoria Cardona; Pedro Carreiro-Martins; Alvaro A Cruz; Wienczyslawa Czarlewski; João A Fonseca; Maia Gotua; Tari Haahtela; Juan Carlos Ivancevich; Piotr Kuna; Violeta Kvedariene; Désirée Erlinda Larenas-Linnemann; Amir Hamzah Abdul Latiff; Mika Mäkelä; Mário Morais-Almeida; Joaquim Mullol; Robert Naclerio; Ken Ohta; Yoshitaka Okamoto; Gabrielle L Onorato; Nikolaos G Papadopoulos; Vincenzo Patella; Frederico S Regateiro; Bolesław Samoliński; Charlotte Suppli Ulrik; Sanna Toppila-Salmi; Arunas Valiulis; Maria-Teresa Ventura; Arzu Yorgancioglu; Torsten Zuberbier; Ioana Agache Journal: Allergy Date: 2021-03 Impact factor: 14.710